Non-alcoholic Fatty Liver Disease SIG: Advances in Genetics and Epigenetics in NAFLD: From Pathogenesis to Personalized Medicine

5 (2 votes)

Recorded On: 11/09/2018

This program will detail recent advances in the understanding of genetic and epigenetic alterations that influence NAFLD and its progression. It will emphasize their impact on the natural history of NAFLD and variability in clinical outcomes. Details on how patient based epigenetic association studies have led to novel insights into disease pathogenesis will be outlined with an emphasis on how this may translate to new therapeutics. Finally, the role of genetics and epigenetics in the evaluation of the patient in the clinic will be addressed – with particular reference to diagnosis, prognosis and therapeutics.

Elizabeth Speliotes

Christopher Glass

Derek Mann

Luca Valenti

Luca Vittorio Valenti, MD, PhD is an associate professor of Internal Medicine and physician scientist for the Department of Transfusion Medicine and Hematology at Fondazione IRCCS Ca’ Granda Ospedale Policlinico Milano, Italy. His main research interest is understanding the molecular basis of metabolic liver diseases, in particular FLD, iron overload disorders and liver cancer, and to apply these discoveries to the clinical management of patients, through the identification of novel biomarkers, therapeutic strategies and clinical algorithms, in a personalized medicine approach. In collaboration with his international network, he has recently discovered new genetic determinants of FLD. In the iron field, he contributed to establishing the role of body iron accumulation in the pathogenesis of metabolic and cardiovascular complications of insulin resistance, and the therapeutic utility of iron depletion. He uses a variety of tools ranging from epidemiological studies in large cohort of individuals with liver biopsies to human and molecular genetics to understand how a gene mutation results into a phenotype.

Prof. Valenti has served as reviewer for several international Journals (>60) including New England Journal of Medicine, The Lancet, Gastroenterology, Gut, Journal of Clinical Investigation, HEPATOLOGY, Journal of Hepatology, Nature Communications, Circulation, Diabetes, Blood, several Scientific Societies (EASL, AISF), European Institutions. Since 2019, he is Honorary Member of Institute of Hepatology at the King’s College of London, the Liver Trust. He is considered an opinion leader in the field of metabolic liver diseases, as testified by invited talks and moderations of scientific sessions in scientific meetings and seminars in Italy, Europe, Asia, and the USA.

Key:

Complete
Failed
Available
Locked
Introduction
Open to view video.
Open to view video.
Insights into Disease Pathogenesis from Population Genetic Studies
Open to view video.
Open to view video. Presenter: Elizabeth Speliotes,
Epigenomic Regulation of Inflammation in NASH
Open to view video.
Open to view video. Presenter: Christopher Glass
Discussion/ Q&A
Open to view video.
Open to view video.
Epigenetics: Modifiers and Therapeutic Targets of Disease Progression in NAFLD
Open to view video.
Open to view video. Presenter: Derek Mann
Genetics and Epigenetics in the Clinic: Personalized Medicine in the Management of NAFLD
Open to view video.
Open to view video. Presenter: Luca Valenti
Final Evaluation
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.